All In Biotech

Drug Trial Radar · NCT05048056

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

79

Actual

Start

Sep 30, 2021

Primary completion

May 17, 2023

Study completion May 17, 2023

Sponsor

Lead sponsor
Akesobio Australia Pty LtdIndustry
Sponsor type
Industry
First posted
Sep 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • PlaceboDrug

    Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1

  • AK120Drug

    AK120 Regimen 1- subcutaneous injection every 2 weeks.

  • AK120Drug

    AK120 Regimen 2- subcutaneous injection every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving an Eczema Area and Severity Index (EASI) 75 responseTime frame: At week 16

Locations

24 sites in 3 countries. Site status is shown where the registry gives one.

  • AkesoBio Investigative Site 2003

    Little Rock, Arkansas

  • AkesoBio Investigative Site 2010

    Canoga Park, California

  • AkesoBio Investigative Site 2021

    San Diego, California

  • AkesoBio Investigative Site 2023

    San Diego, California

  • AkesoBio Investigative Site 2017

    San Francisco, California

  • AkesoBio Investigative Site 2020

    Sherman Oaks, California

  • AkesoBio Investigative Site 2009

    Hialeah, Florida

  • AkesoBio Investigative Site 2001

    Hollywood, Florida

  • AkesoBio Investigative Site 2011

    Miami, Florida

  • AkesoBio Investigative Site 2002

    Weston, Florida

  • AkesoBio Investigative Site 2022

    Ridgeland, Mississippi

  • AkesoBio Investigative Site 2015

    Las Vegas, Nevada

  • AkesoBio Investigative Site 2013

    Spartanburg, South Carolina

  • AkesoBio Investigative Site 2005

    Rapid City, South Dakota

  • AkesoBio Investigative Site 2004

    Houston, Texas

  • AkesoBio Investigative Site 2018

    Houston, Texas

  • AkesoBio Investigative Site 3003

    Sydney, New South Wales, Australia

  • AkesoBio Investigative Site 3002

    Woolloongabba, Queensland, Australia

  • AkesoBio Investigative Site 3001

    Camberwell, Victoria, Australia

  • AkesoBio Investigative Site 4003

    Auckland, New Zealand

  • AkesoBio Investigative Site 4001

    Auckland, New Zealand

  • AkesoBio Investigative Site 4005

    Christchurch, New Zealand

  • AkesoBio Investigative Site 4004

    Hamilton, New Zealand

  • AkesoBio Investigative Site 4004

    Wellington, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.